Financial Results - Standalone (₹ in Lakhs)

Quarterly Performance Comparison:

  • Q1 FY27 (Jun 2026): Net loss of ₹4.22 crore
  • Q4 FY26 (Mar 2026): Net loss of ₹15.73 crore
  • Q1 FY26 (Jun 2025): Net profit of ₹5.21 crore

Income Statement Highlights for Q1 FY27:

  • Total Income: ₹64.93 lakhs
  • Total Expenses: ₹51.96 lakhs
  • Profit/(Loss) before exceptional items and tax: ₹(4.05) lakhs
  • Exceptional items: ₹3.55 lakhs
  • Profit/(Loss) before tax: ₹(19.00) lakhs
  • Tax expense: ₹(1.66) lakhs (Deferred tax)
  • Net profit/(loss) after tax: ₹(4.22) lakhs
  • Total comprehensive income: ₹(4.71) lakhs

Key Metrics:

  • Paid-up equity share capital: ₹726.32 lakhs (Face value ₹10 each)
  • Weighted average number of equity shares: 54,81,489 shares

Financial Results - Consolidated (₹ in Lakhs)

Quarterly Performance Comparison:

  • Q1 FY27 (Jun 2026): Net loss of ₹118.82 lakhs
  • Q4 FY26 (Mar 2026): Net loss of ₹111.77 lakhs
  • Q1 FY26 (Jun 2025): Net loss of ₹17.01 lakhs

Income Statement Highlights for Q1 FY27:

  • Total Income: ₹479.07 lakhs
  • Total Expenses: ₹592.16 lakhs
  • Profit/(Loss) before tax and exceptional items: ₹(114.57) lakhs
  • Exceptional items: ₹(19.00) lakhs
  • Profit/(Loss) before tax: ₹(114.57) lakhs
  • Tax expense: ₹4.25 lakhs (Current tax)
  • Net profit/(loss) after tax: ₹(118.82) lakhs
  • Total comprehensive income: ₹(119.61) lakhs

Segment-wise Performance (Q1 FY27):

  • Cashew processing: Revenue ₹35.41 lakhs, Segment loss ₹(81.93) lakhs
  • Tissue Culture: Revenue ₹67.14 lakhs
  • Trading: Revenue ₹102.55 lakhs, Segment loss ₹(19.91) lakhs
  • Unallocable: Loss ₹(12.74) lakhs

Subsidiary Financial Status

Aranya Consulting and Biotech LLP (formerly Aranya Agri Biotech LLP):

  • Accumulated losses of ₹1,494 lakhs as of March 31, 2026
  • Current year loss (up to June 30, 2026): ₹0.69 lakhs
  • Financial results prepared on going concern basis

Biospan Scientific LLP:

  • Accumulated losses of ₹157 lakhs as of March 31, 2019
  • Management impaired investment of ₹183 lakhs in FY 2018-19 (treated as exceptional item)
  • Financial results prepared on going concern basis as management explores revival possibilities

Biospan Contamination Control Solutions Pvt. Ltd:

  • Accumulated losses of ₹742 lakhs as of June 30, 2026
  • Total liabilities exceeded total assets by ₹752 lakhs
  • Financial results prepared on going concern basis as management believes losses are temporary

Preferential Issue Proceeds Utilization

  • Total amount raised: ₹579.36 lakhs
  • Amount utilized: ₹372.96 lakhs
  • Unutilized amount: ₹127.04 lakhs
  • No deviation or variation in utilization of preferential issue proceeds
  • Unutilized amount will be utilized towards stated objects of the issue

Board Meeting Details

  • Meeting held on August 11, 2026
  • Commenced at 11:15 IST, concluded at 16:30 IST
  • Approved unaudited standalone and consolidated financial results
  • Results reviewed by Audit Committee

Accounting Standards

Financial results prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of Companies Act, 2013.

Availability of Results

Results available on company website www.span.in and BSE website www.bseindia.com